Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

Lymphoma research presented at ASCO 2025 highlighted investigational treatments for FL, HL, and DLBCL as well as a revised staging system for NKTCL.

Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

A survey of more than 20,000 patients revealed a lack of trust in information about cancer, whether it comes from scientists, doctors, or other sources.

Omitting pelvic lymphadenectomy may be beneficial for patients with early-stage cervical cancer undergoing sentinel lymph node biopsy and radical hysterectomy.

(HealthDay News) — More than 460 employees who were laid off from their jobs at the US Centers for Disease Control and Prevention (CDC) are being rehired, the Associated Press reported last week.

(HealthDay News) — Circulating tumor DNA (ctDNA) can be detected more than 3 years prior to a clinical cancer diagnosis, according to a research brief published in Cancer Discovery.

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for chemotherapy in certain patients with NSCLC.

The FDA has approved Zusduri (mitomycin intravesical solution) to treat adults with recurrent, low-grade, intermediate-risk NMIBC.

The US Food and Drug Administration (FDA) has approved a new tablet formulation of Brukinsa (zanubrutinib), which is expected to replace the current capsule formulation in October 2025. Brukinsa, a ...

Keytruda (pembrolizumab) is now approved as perioperative treatment for patients with head and neck squamous cell carcinoma.

Credit: Getty Images The Clinical Advisor spoke with Carlos Gutiérrez, EdD, MMS, PA-C, about the impact of executive orders on LGBTQ+ health care. To gauge how the changing landscape surrounding ...